The FDA’s ODAC sought to determine whether cilta-cel has a favorable benefit-risk profile for patients with multiple myeloma. The FDA’s ODAC unanimously voted that the potential benefits of cilta-cel outweigh its risks for its proposed indication in patients with multiple myeloma.
The FDA’s ODAC sought to determine whether cilta-cel has a favorable benefit-risk profile for patients with multiple myeloma. The FDA’s ODAC unanimously voted that the potential benefits of cilta-cel outweigh its risks for its proposed indication in patients with multiple myeloma.